Systemic Anti-Cancer Therapy Regimen Library
UKALL14 with RITUximab [over 40 years] [for transplant] - Consolidation [Cycle 4] (LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [for transplant])
Treatment Overview
Start after count recovery from Consolidation/delayed intensification Cycle 3, with neutrophils greater than 0.75 x 109/L and platelets greater than 75 x 109/L.
Cycle 1 - 21 days
cytarabine: Administer by subcutaneous injection (as above) or alternatively administer intravenously as per institutional practice.
metHOTREXATe intrathecal:
- Day of administration can be moved +/- 3 days.
- For Ommaya reservoir reduce dose to 6 mg intraventricularly.
Cycle details
Cycle 1 - 21 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| cytarabine | 75 mg/m² Once daily | subcutaneous injection | 1 to 5 | |
| etoposide (as phosphate) * | 100 mg/m² Once daily | intravenous | 1 to 5 | 60 minutes |
| metHOTREXATe | 12 mg flat dosing | intrathecal injection | 1 |
cytarabine: Administer by subcutaneous injection (as above) or alternatively administer intravenously as per institutional practice.
metHOTREXATe intrathecal:
- Day of administration can be moved +/- 3 days.
- For Ommaya reservoir reduce dose to 6 mg intraventricularly.
Full details
Cycle 1 - 21 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 75 mg/m² Once daily | subcutaneous injection |
Instructions:
Or administer intravenously as per institutional practice. |
|
| etoposide (as phosphate) * | 100 mg/m² Once daily | intravenous | 60 minutes | |
| metHOTREXATe | 12 mg flat dosing | intrathecal injection |
Instructions:
|
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 75 mg/m² Once daily | subcutaneous injection |
Instructions:
Or administer intravenously as per institutional practice. |
|
| etoposide (as phosphate) * | 100 mg/m² Once daily | intravenous | 60 minutes |
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 75 mg/m² Once daily | subcutaneous injection |
Instructions:
Or administer intravenously as per institutional practice. |
|
| etoposide (as phosphate) * | 100 mg/m² Once daily | intravenous | 60 minutes |
Day: 4
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 75 mg/m² Once daily | subcutaneous injection |
Instructions:
Or administer intravenously as per institutional practice. |
|
| etoposide (as phosphate) * | 100 mg/m² Once daily | intravenous | 60 minutes |
Day: 5
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 75 mg/m² Once daily | subcutaneous injection |
Instructions:
Or administer intravenously as per institutional practice. |
|
| etoposide (as phosphate) * | 100 mg/m² Once daily | intravenous | 60 minutes |
Supportive Care Factors
| Factor | Value |
|---|---|
| Antifungal prophylaxis: | Routine antifungal prophylaxis recommended |
| Antiviral prophylaxis for hepatitis B virus: | Required for anti–HBc positive patients at risk of reactivation |
| Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis recommended |
| Emetogenicity: | Low |
| Pneumocystis jirovecii pneumonia (PJP) prophylaxis: | Routine antibiotic prophylaxis recommended |
References
No references
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.